Cargando…
The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke
Ischemic stroke (IS) is a common neurological disorder associated with high disability rates and mortality rates. At present, recombinant tissue plasminogen activator (r-tPA) is the only US(FDA)-approved drug for IS. However, due to the narrow therapeutic window and risk of intracerebral hemorrhage,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148018/ https://www.ncbi.nlm.nih.gov/pubmed/35630576 http://dx.doi.org/10.3390/molecules27103099 |
_version_ | 1784716949572288512 |
---|---|
author | Li, Xing-Hua Yin, Feng-Ting Zhou, Xiao-Hang Zhang, Ai-Hua Sun, Hui Yan, Guang-Li Wang, Xi-Jun |
author_facet | Li, Xing-Hua Yin, Feng-Ting Zhou, Xiao-Hang Zhang, Ai-Hua Sun, Hui Yan, Guang-Li Wang, Xi-Jun |
author_sort | Li, Xing-Hua |
collection | PubMed |
description | Ischemic stroke (IS) is a common neurological disorder associated with high disability rates and mortality rates. At present, recombinant tissue plasminogen activator (r-tPA) is the only US(FDA)-approved drug for IS. However, due to the narrow therapeutic window and risk of intracerebral hemorrhage, r-tPA is currently used in less than 5% of stroke patients. Natural compounds have been widely used in the treatment of IS in China and have a wide range of therapeutic effects on IS by regulating multiple targets and signaling pathways. The keywords “ischemia stroke, traditional Chinese Medicine, Chinese herbal medicine, natural compounds” were used to search the relevant literature in PubMed and other databases over the past five years. The results showed that JAK/STAT, NF-κB, MAPK, Notch, Nrf2, and PI3K/Akt are the key pathways, and SIRT1, MMP9, TLR4, HIF-α are the key targets for the natural compounds from traditional Chinese medicine in treating IS. This study aims to update and summarize the signaling pathways and targets of natural compounds in the treatment of IS, and provide a base of information for the future development of effective treatments for IS. |
format | Online Article Text |
id | pubmed-9148018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91480182022-05-29 The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke Li, Xing-Hua Yin, Feng-Ting Zhou, Xiao-Hang Zhang, Ai-Hua Sun, Hui Yan, Guang-Li Wang, Xi-Jun Molecules Review Ischemic stroke (IS) is a common neurological disorder associated with high disability rates and mortality rates. At present, recombinant tissue plasminogen activator (r-tPA) is the only US(FDA)-approved drug for IS. However, due to the narrow therapeutic window and risk of intracerebral hemorrhage, r-tPA is currently used in less than 5% of stroke patients. Natural compounds have been widely used in the treatment of IS in China and have a wide range of therapeutic effects on IS by regulating multiple targets and signaling pathways. The keywords “ischemia stroke, traditional Chinese Medicine, Chinese herbal medicine, natural compounds” were used to search the relevant literature in PubMed and other databases over the past five years. The results showed that JAK/STAT, NF-κB, MAPK, Notch, Nrf2, and PI3K/Akt are the key pathways, and SIRT1, MMP9, TLR4, HIF-α are the key targets for the natural compounds from traditional Chinese medicine in treating IS. This study aims to update and summarize the signaling pathways and targets of natural compounds in the treatment of IS, and provide a base of information for the future development of effective treatments for IS. MDPI 2022-05-12 /pmc/articles/PMC9148018/ /pubmed/35630576 http://dx.doi.org/10.3390/molecules27103099 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Li, Xing-Hua Yin, Feng-Ting Zhou, Xiao-Hang Zhang, Ai-Hua Sun, Hui Yan, Guang-Li Wang, Xi-Jun The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke |
title | The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke |
title_full | The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke |
title_fullStr | The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke |
title_full_unstemmed | The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke |
title_short | The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke |
title_sort | signaling pathways and targets of natural compounds from traditional chinese medicine in treating ischemic stroke |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148018/ https://www.ncbi.nlm.nih.gov/pubmed/35630576 http://dx.doi.org/10.3390/molecules27103099 |
work_keys_str_mv | AT lixinghua thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT yinfengting thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT zhouxiaohang thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT zhangaihua thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT sunhui thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT yanguangli thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT wangxijun thesignalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT lixinghua signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT yinfengting signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT zhouxiaohang signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT zhangaihua signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT sunhui signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT yanguangli signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke AT wangxijun signalingpathwaysandtargetsofnaturalcompoundsfromtraditionalchinesemedicineintreatingischemicstroke |